ClinicalTrials.gg
RecruitingNCT07296744SUPPORT IIUpdated Nov 18, 2026

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

An interventional study of The Supira System and Impella in Coronary Artery Disease, High Risk Percutaneous Coronary Intervention and Interventional Cardiology, sponsored by Supira Medical. Recruiting at 27 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Supira Medical · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 18, 2026Site recruiting status changed3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,105 studies in Coronary Artery Disease with a site in United States — 101 open to participants now, 146 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Planned enrollment
192nd of 746
358 · median 107
Started
2026
with 23 others
No phase
353 of 1,105
43 open now
Primary completion
2027-11
later than 88 of 143 live
Registered
1,082nd of 1,105
by date

Among the 1,105 studies in Coronary Artery Disease with a site in United States, this one is the 192nd largest by planned enrollment of the 746 interventional ones that give a count, is one of 24 that started in 2026, is one of 353 with no phase, reaches primary completion later than 88 of the 143 other live ones, and was the 1,082nd registered.

Coronary Artery Disease

4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

101 of the 1,105 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 101 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,105 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. Eligible patients will be randomized to undergo HRPCI with either the Supira System (investigational device) or the commercially available Impella systems (comparator device).

Read the detailed description

The Supira System is a minimally invasive percutaneous ventricular assist device (pVAD) that is intended to provide temporary hemodynamic support (≤ 4 hours) to patients undergoing HRPCI. The Supira Catheter is inserted percutaneously through the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with the pump outlet remaining in the ascending aorta. The pump portion of the Catheter compresses during insertion in the Introducer Sheath and re-expands during use. It actively unloads the left ventricle by pumping blood from the ventricle into the ascending aorta and systemic circulation.

03

Conditions studied

  • Coronary Artery Disease
  • High Risk Percutaneous Coronary Intervention
  • Interventional Cardiology
  • Mechanical Circulatory Support

Keywords

  • Percutaneous ventricular assist device
  • Supira System
  • Mechanical Circulatory Support
  • US Pivotal
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hemodynamically stable and will undergo elective or urgent (not emergent) HRPCI, where hemodynamic support is deemed necessary, as determined by the institutional Heart Team
  • granted by the subject or legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock or acutely decompensated pre-existing chronic heart failure
  • Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit
  • Left ventricular thrombus
  • Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the device or the comparator device
  • Ongoing renal replacement therapy with dialysis
  • Presence of decompensated liver disease; severe liver dysfunction
  • Infection of the proposed procedural access site or active infection
  • Known to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol
  • Any condition, coagulopathy, planned procedure or that requires discontinuation of antiplatelet and/or anticoagulant therapy within 90 days of the index procedure
  • Breastfeeding or pregnant or planning to become pregnant within 90 days of the HRPCI procedure
  • Currently participating in active follow-up phase of another clinical study of an investigational drug or device or planning to enroll in such a study within 90 days of the HRPCI procedure
  • Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written and/or to comply with study procedures
  • Considered to be part of a vulnerable population per the investigator's assessment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
358 participants (estimated)

Study arms

  • Experimental
    Supira System

    Subjects receiving the Supira System

    Device: The Supira System

  • Active comparator
    Impella

    Subjects receiving the Impella

    Device: Impella

Interventions

  • DeviceThe Supira System

    The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent HRPCI performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option.

  • DeviceImpella

    The current commercially available Impella CP with SmartAssist Catheter is indicated for providing temporary (≤ 6 hours) ventricular support during elective or urgent high risk percutaneous coronary i

06

What researchers measure

Primary outcomes

  1. Composite Safety and Efficacy Outcomes

    * All-cause death * Myocardial infarction * Stroke or transient ischemic attack * Major bleeding * Major access site-related vascular complications * Acute Kidney Injury * Unplanned repeat revascularization * Sustained hypotensiona during mechanical circulatory support * Arrythmia requiring cardioversion during pump use

    Time frame: 30 days

Secondary outcomes

  1. Secondary Outcome Measures

    Individual rates of the following outcomes: * All-cause death * MI * Stroke or TIA * Major bleeding * Major access site-related vascular complications * AKI * Unplanned repeat vascularization * Cardiovascular re-hospitalization * Ventricular arrhythmia requiring cardioversion * Major cardiac structural complications * Major Hemolysis

    Time frame: 30 and 90 days

07

Study locations

27 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 18 months is below that.

Counting every sponsor, half of 932 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Dec 22, 2025
StartActual
May 11, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Virtua Health · Camden, United StatesNot yet recruiting→Recruiting
  • Providence · Portland, United StatesNot yet recruiting→Recruiting
  • Mission Health · Asheville, United StatesNot yet recruiting→Recruiting
Show 3 added (3 United States)
  • University of Miami · Miami, United States
  • The Valley Hospital · Paramus, United States
  • University of Michigan · Ann Arbor, United States
across 4 updates, Sep 30, 2026 – Nov 18, 2026
Show all 4 updates
  1. Nov 18, 2026
    1 site added
    Show site
    • University of Michigan · Ann Arbor, United States
  2. Nov 2, 2026
    1 site added
    Show site
    • The Valley Hospital · Paramus, United States
  3. Oct 19, 2026
    1 site added. Mission Health is now Recruiting
    Show site
    • University of Miami · Miami, United States
    + 1 other change: verification date
  4. Sep 30, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Virtua Health · Camden, United StatesNot yet recruiting→Recruiting
    • Providence · Portland, United StatesNot yet recruiting→Recruiting
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07296744
Lead sponsor
Supira Medical
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
May 11, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Supira Medical
Contact
clinical@supiramedical.com
(669) 330-0883
Chris DeMorett
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion